RIMEL REBECCA W
Known title: DirectorCIK: 0001250391
Associated companies
Transaction History
| BDX | ▼ Sell | Open Market | 500 | $130K | 9/8/2021 | View on chart |
| BDX | ▼ Sell | Open Market | 500 | $129K | 9/3/2021 | View on chart |
| BDX | ▼ Sell | Open Market | 244 | $62K | 9/2/2021 | View on chart |
| BDX | ▼ Sell | Open Market | 207 | $52K | 8/30/2021 | View on chart |
| BDX | ▼ Sell | Open Market | 207 | $52K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.